Communiqués UCB

Actions

UCB

BE0003739530

Produits pharmaceutiques

PEA

Temps réel Euronext Bruxelles 14:04:14 08/10/2026			Varia. 5j.	Varia. 1 janv.
203,50 ^EUR	-0,15 %		+1,09 %	-14,71 %

04:36	Transcript : UCB SA - Special Call
30/09	Le médicament expérimental de Merck contre une maladie cutanée atteint son objectif dans une étude de phase intermédiaire	RE

Communiqués

30/09	UCB : announces new data at EADV 2026 supporting earlier use of BIMZELX (bimekizumab) for treating hidradenitis suppurativa	PU
29/09	UCB : data presented at 2026 AANEM Annual Meeting and MGFA Scientific Session underscore leadership in advancing targeted treatments for gMG	PU
28/09	Why minimal symptom expression matters: raising the bar for people living with myasthenia gravis	PU
25/09	The Best Conversations Start Early: Coffee Reflections Ahead of EADV 2026	PU
09/09	UCB : receives U.S. FDA Breakthrough Therapy Designation for CIMZIA (certolizumab pegol) in pregnant women with antiphospholipid syndrome (APS)	PU
08/09	UCB : Helping families and clinicians connect the signs that may point to TK2d	PU
03/09	Advancing the future of rare disease diagnosis: Aspire4Rare's next chapter	PU
31/08	UCB : Transparency notification Wellington Management Group LLP	PU
30/07	UCB : Delivering today, shaping what comes next	PU
30/07	UCB : Delivers Strong Results, Raises 2026 Guidance and Positions for Next Growth Phase	PU
08/07	UCB : presents latest data from its targeted generalized myasthenia gravis treatment portfolio at International Congress on Neuromuscular Diseases 2026	PU
03/07	UCB : FASTRAX working session highlights progress in axSpA diagnosis	PU
30/06	Changing the Way We Care for gMG: Why Patient Choice and Innovation Must Lead the Way	PU
17/06	UCB : completes acquisition of Candid Therapeutics, strengthening next generation immunology pipeline	PU
12/06	Reflections from EULAR 2026: advancing early control of inflammation	PU
05/06	UCB - EULAR 2026, Dapirolizumab Pegol Shows Potential to Reduce Flare Rates and Maintain Disease Control in Systemic Lupus Erythematosus	AQ
05/06	UCB : New EULAR 2026 data show CIMZIA (certolizumab pegol) delivered consistent effect in rheumatoid arthritis, regardless of rheumatoid factor (RF) levels	PU
03/06	UCB : BIMZELX(bimekizumab) data at EULAR 2026 show early and sustained inflammation control can improve patient reported outcomes and limit disease progression in PsA and axSpA	PU
02/06	UCB : completes acquisition of Neurona Therapeutics, advancing its leadership as innovator in epilepsy through regenerative science	PU
02/06	UCB : presents research at EUROMIT 2026 highlighting burden of care, need for earlier diagnosis, and impact of pyrimidine nucleoside therapy on people living with TK2d	PU
01/06	UCB : and Biogen Announce Publication in The Lancet of Positive Dapirolizumab Pegol (DZP) Phase 3 Study Results in Systemic Lupus Erythematosus	PU
20/05	UCB : Financial Reporting Document	PU
19/05	BIMZELX[®](bimekizumab) demonstrates superior efficacy over SKYRIZI[®] (risankizumab) in psoriatic arthritis: BE BOLD Week 16 data	PU
08/05	UCB : Celebrating a decade of partnership advancing digital innovation in epilepsy care	PU
07/05	UCB : Cancer Research UK and Cancer Research Horizons announce new strategic alliance to accelerate development of novel cancer therapies	PU